The most common mechanisms for resistance in patients with chronic myeloid leukemia (CML) receiving imatinib mesylate are BCR-ABL kinase domain (KD) mutations. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.